Palisade Bio (PALI)
(Delayed Data from NSDQ)
$3.67 USD
+0.02 (0.55%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $3.66 -0.01 (-0.27%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
PALI 3.67 +0.02(0.55%)
Will PALI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PALI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PALI
Bears are Losing Control Over Palisade Bio (PALI), Here's Why It's a 'Buy' Now
Palisade (PALI) In-Licenses Rights for IBD Candidate, Stock Up
PALI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Palisade Bio, Inc. (PALI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Palisade Bio, Inc. (PALI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Palisade (PALI) Enrolls First Patient in LB1148 Study in China
Other News for PALI
Palisade Bio Participates in Virtual Investor ?What this Means? Segment
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108
Palisade Bio completes microbiome study on PALI-2108
Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108
Palisade announces EPO issued decision to grant notice for patent on PALI-2108